JP2012506394A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506394A5
JP2012506394A5 JP2011532532A JP2011532532A JP2012506394A5 JP 2012506394 A5 JP2012506394 A5 JP 2012506394A5 JP 2011532532 A JP2011532532 A JP 2011532532A JP 2011532532 A JP2011532532 A JP 2011532532A JP 2012506394 A5 JP2012506394 A5 JP 2012506394A5
Authority
JP
Japan
Prior art keywords
use according
tumor
days
immune cytokine
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011532532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/007533 external-priority patent/WO2010046097A1/en
Publication of JP2012506394A publication Critical patent/JP2012506394A/ja
Publication of JP2012506394A5 publication Critical patent/JP2012506394A5/ja
Pending legal-status Critical Current

Links

JP2011532532A 2008-10-21 2009-10-21 放射線および免疫サイトカインによる癌治療 Pending JP2012506394A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10714608P 2008-10-21 2008-10-21
US61/107,146 2008-10-21
PCT/EP2009/007533 WO2010046097A1 (en) 2008-10-21 2009-10-21 Cancer treatments with radiation and immunocytokines

Publications (2)

Publication Number Publication Date
JP2012506394A JP2012506394A (ja) 2012-03-15
JP2012506394A5 true JP2012506394A5 (enExample) 2012-12-06

Family

ID=41510762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532532A Pending JP2012506394A (ja) 2008-10-21 2009-10-21 放射線および免疫サイトカインによる癌治療

Country Status (12)

Country Link
US (1) US20100330029A1 (enExample)
EP (1) EP2337579A1 (enExample)
JP (1) JP2012506394A (enExample)
KR (1) KR20110086101A (enExample)
CN (1) CN102196815A (enExample)
AU (1) AU2009306711A1 (enExample)
BR (1) BRPI0919857A2 (enExample)
CA (1) CA2741130A1 (enExample)
EA (1) EA201100626A1 (enExample)
MX (1) MX2011004193A (enExample)
WO (1) WO2010046097A1 (enExample)
ZA (1) ZA201103726B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN112768029B (zh) * 2020-12-27 2023-10-13 上海市东方医院(同济大学附属东方医院) 一种基于单细胞测序的组合用药推荐设备、方法及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110538A1 (en) * 1999-12-28 2002-08-15 Health Research, Inc. Methods and products for tumor immunotherapy using cytokines
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US20060263368A1 (en) * 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo

Similar Documents

Publication Publication Date Title
Bae et al. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea
JP2009539769A5 (enExample)
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2008505857A5 (enExample)
JP2014530220A5 (enExample)
JP2013075922A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
JP2013155188A5 (enExample)
JP2016539156A5 (enExample)
JP2015523407A5 (enExample)
JP2013516493A5 (enExample)
JP2016526531A5 (enExample)
JP2012107063A5 (enExample)
JP2017501140A5 (enExample)
JP2013518124A5 (enExample)
JP2017512194A5 (enExample)
JP2015507020A5 (enExample)
JP2019526559A5 (enExample)
JP2013511975A5 (enExample)
JP2012504161A5 (enExample)
JP2017061488A5 (enExample)
JP2015515974A5 (enExample)
JP2022512158A5 (enExample)
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
JP2017502058A5 (enExample)